Central Nervous System (CNS) API Products
Explorar Sistema Nervoso Central (SNC) Products
Apremilast (amorfo)
Sistema Nervoso Central (SNC)
Cloridrato De Atomoxetina
Sistema Nervoso Central (SNC)
Mesilato De Benztropina
Sistema Nervoso Central (SNC)
Donepezil HCl
Sistema Nervoso Central (SNC)
Edaravone
Sistema Nervoso Central (SNC)
Acetato De Eslicarbazepina
Sistema Nervoso Central (SNC)
Eszopiclone
Sistema Nervoso Central (SNC)
Levetiracetam
Sistema Nervoso Central (SNC)
Lumateperone Tosylate
Sistema Nervoso Central (SNC)
Cloridrato De Lurasidona
Sistema Nervoso Central (SNC)
Cloridrato De Memantina
Sistema Nervoso Central (SNC)
Pregabalina
Sistema Nervoso Central (SNC)
Rimegepant
Sistema Nervoso Central (SNC)
Risperidon
Sistema Nervoso Central (SNC)
Tartarato De Hidrogênio Da Rivastigmina
Sistema Nervoso Central (SNC)
Ropinirole Hydrochloride
Sistema Nervoso Central (SNC)
Siponimod
Sistema Nervoso Central (SNC)
Sugammadex Sodium
Sistema Nervoso Central (SNC)
Cloridrato De Tizanidina
Sistema Nervoso Central (SNC)
Xanomeline
Sistema Nervoso Central (SNC)
Cloridrato De Ziprasidona
Sistema Nervoso Central (SNC)
Fluoxetine
Sistema Nervoso Central (SNC)
Fumarato De Quetiapina
Sistema Nervoso Central (SNC)
USPs of our CNS APIs
- Firm PSD control to help maintain consistency of manufacturing process.
- Sufficient capacity to meet our customer’s global leadership requirements.
- Reliable KSM suppliers in India with timely deliveries and stringent specifications.
- IP compliant process.
- Well-controlled all the plausible impurities within the specified limit.
- Commercially available starting materials.
- Schemes of starting material evaluated.
- Flexible business models to support registrations.
- Adequate capacity available to supply development quantity in short lead time.
- Free from nitrosamine impurities.
- QBD (Quality by Design) based API development for consistent quality profile.
- Continuous improvement in place to achieve cost and quality excellence.
- Process safety and scalability.
- APIs suitable for global formulation development.
- Fully backward integration process.
- Compliant to all pharmacopeia’s.
- Multiple domestic sources for KSMs available.
- Able to match a wide range of particle size requirements.
Get access to Dr. Reddy's largest CNS API portfolios to support your formulation success
Dr. Reddy’s is one of the leading generic pharmaceutical companies and CNS API suppliers in the development and manufacturing of CNS APIs used in formulations to treat indications in the central nervous system (CNS) therapy area. Our CNS API product portfolio is broad-based, including APIs in the class of atypical antipsychotics, anticholinergics, Nrf2 activators, cholinesterase inhibitors, antioxidants, and GnRH antagonists.
Explorar other Therapeutic categories.
CNS -FAQ
Our CNS API product portfolio is broad-based, including APIs in the class of atypical antipsychotics, anticholinergics, Nrf2 activators, cholinesterase inhibitors, antioxidants, and GnRH antagonists.
They can act either as neurotransmitter agonists, such as the opioids, which mimic the action of enkephalin, or they can block receptor function. Receptor antagonism is a common mechanism of action for CNS drugs.
The global central nervous system therapeutic market was valued at 116.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.4% from 2021 to 2028. Advancements in diagnostics and therapeutics of CNS diseases are expected to increase the treatment rate globally.
Used to treat insomnia (trouble sleeping), anxiety, panic attacks, and seizures. They may also be used to relieve anxiety and tension before surgery. Examples of CNS depressants are benzodiazepines, barbiturates, and certain sleep medicines.
Aviso legal
Nenhuma informação neste site, incluindo qualquer referência a qualquer produto ou serviço, constitui uma oferta de venda ou pode ser interpretada como representando uma oferta de venda. Produtos protegidos por patentes válidas não são oferecidos ou fornecidos para uso comercial. No entanto, em certos casos, a critério exclusivo do Dr. Reddy e sujeito a requisitos legais locais, as quantidades de pesquisa de tais produtos podem ser oferecidas para fins de submissões regulatórias sob a Seção 107A da Lei de Patentes da Índia (isenção Bolar), onde quer que tais isenções regulatórias existam. Os compradores devem fazer sua avaliação independente do produto ou serviço, incluindo o cenário de patentes em seus respectivos mercados e serão responsáveis por todas as responsabilidades relacionadas a patentes. O Dr. Reddy se isenta de todas as garantias, expressas ou implícitas, incluindo, entre outras, garantias de comercialização, adequação a uma finalidade específica e não violação.